The technology transfer project, which began last year, aims to help low- and middle-income countries manufacture this type of vaccine to the extent required, and in accordance with international standards.
RNA is a sophisticated technology used by companies such as Pfizer-Biontech and Moderna in the production of their protective vaccines against “Covid-19”.
The World Health Organization established its center for transfer of RNA technology, after rich countries stockpiled vaccines and companies prioritizing governments that can pay the highest price, making low- and middle-income countries at the bottom of the waiting list for Covid-19 vaccines.
The Director-General of the Organization, Tedros Adhanom Ghebreyesus, said in a statement that the “Covid-19” pandemic has shown more than anything that reliance on a few companies to supply the world with general products is something that entails restrictions and risks.
“The best way to address health emergencies and achieve universal health coverage, in the medium and long term, is to significantly increase the capacity of all regions to manufacture the health products they need,” he added.
South African President Cyril Ramaphosa praised the project and urged the global “Cofax” mechanism for the distribution of vaccines and the Global Alliance for Vaccines and Immunization (GAVI) to purchase vaccines from local manufacturing centers in African countries.
“The lack of markets for vaccines made by the African continent is something that should interest us all,” Ramaphosa said.
“Organizations like Kovacs and Jaffee should commit to buying vaccines from local manufacturers rather than going outside these centers that are being set up,” he added.